UK markets close in 3 hours 8 minutes

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,057.00-3.00 (-0.28%)
As of 12:58PM BST. Market open.

MaxCyte, Inc.

22 Firstfield Road
Suite 110
Gaithersburg, MD 20878
United States
301 944 1700

IndustryDiagnostics & Research
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Douglas Arthur DoerflerFounder, Pres, CEO & Exec. Director891.46kN/A1956
Ms. Amanda Louise Murphy C.F.A., CFAChief Financial Officer603.99kN/A1977
Mr. Ronald Evan Holtz CPA, Ph.D.Sr. VP & Chief Accounting OfficerN/AN/A1958
Mr. Sean MenarguezBus. Intelligence, Strategy & Investor RelationsN/AN/AN/A
Mr. Maher MasoudExec. VP & Gen. CounselN/AN/A1975
Mr. Thomas Michael RossExec. VP of Global Sales & MarketingN/AN/A1961
Mr. Kevin GutshallVP of Strategy & Corp. Devel.N/AN/AN/A
Dr. James Brady Ph.D.Sr. VP of Technical Applications & Customer SupportN/AN/AN/A
Dr. Claudio Dansky Ullmann M.D.Chief Medical OfficerN/AN/AN/A
Dr. Sarah Haecker Meeks Ph.D.Sr. VP of Bus. Devel.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate governance

MaxCyte, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.